explore -WSS

explore

author：leisure time 2025-10-01 17:20:09 - browse：77689

Adam's take main illustration — Molly Ferguson/STAT

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Diverse clinical trials: Why aren’t we there yet?

Wikipedia

WSS

Diverse clinical trials: Why aren’t we there yet?

New weight loss drugs vying to be the next Wegovy or Mounjaro

Telehealth for opioid use disorder is lifesaving

New weight loss drugs vying to be the next Wegovy or Mounjaro

Listen: Vivek Ramaswamy's star turn & leaky drug data

How the first Native Hawaiian psychiatrist helped diversify medicine

hotspot

explore

hotspot

Sports medicine is finally prioritizing gender equality

White House touts steps to stem shortages of cancer treatments

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Health officials lay out plans to cope with respiratory virus season

As demand for Covid shots wanes, Moderna seeks its next success

Listen: Vivek Ramaswamy's star turn & leaky drug data

Sports medicine is finally prioritizing gender equality

Trans patients at the end of life deserve respect and dignity

The high cost of giving birth even with insurance

Will the IRA bring competition to the biologics market?

hotspot

How the first Native Hawaiian psychiatrist helped diversify medicine

IRA could hurt research into orphan drugs for rare diseases

Regeneron agrees to White House price limits on anti

Generate Biomedicines machine learning biotech raises $273M

Popular nasal decongestant doesn't actually relieve congestion

New weight loss drugs vying to be the next Wegovy or Mounjaro

Wikipedia

entertainment

hotspot

leisure time